988 - A Mental Health Lifeline
988 is a mental health crisis line. A shortened version of the 1-800-273-TALK (8255), this line is specifically used for any mental health related emergency.
FDA Clears TMS Use for Obsessive-Compulsion Disorder (OCD)
Obsessive Compulsion Disorder (OCD) is a mental health disorder that consists of uncontrollable fears and thoughts that interfere with an individual's everyday life.
The company Neuronetics, who created NeuroStar and was the first FDA approved TMS system, recently received FDA clearance for the use of TMS to treat patients with Obsessive-Compulsion Disorders. This system is a transcranial magnetic stimulation system that uses noninvasive magnetic fields to induce activity in specific localized regions of the brain. This device was previously known and approved for the treatment of treatment resistant depressive disorder. Until recently, the FDA has approved the use of this device to treat Obsessive-Compulsion Disorder (OCD) allowing healthcare providers to treat both OCD and major depressive disorder.
This new approval means TMS could help even more individuals experiencing mental health disorders and reach a greater population.
Read about the recent clearance for OCD here.
You Might Also Enjoy...
TMS and Its Wide Application
FDA's approval of TMS for Major Depressive Disorder (MDD) in 2008 has sparked researchers to take a dive and explore further implications of TMS for other drug-resistant psychiatric disorders.
Study Supports the Use of Repetitive TMS for Treatment Resistant Depression
A study in France has found that 1 in 4 individuals may achieve remission for treatment resistant depression with repetitive TMS.
List of TMS Devices that Have Been Cleared by the FDA to Treat Major Depression
Here is a list of TMS devices currently cleared by the FDA to treat major depression.
TMS for Parkinson's Disease
Read about how transcranial magnetic stimulation (TMS) can be used to help target the motor symptoms of Parkinson's disease.
SAINT Protocol Now Cleared by the FDA
Read about how the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for the treatment of major depressive disorder is now cleared by the US Food & Drug Administration (FDA).